

**Armen Donabedian PhD
Scientific Technical Advisor and Chief
Vaccine Advanced Development Branch
Influenza and Emerging Diseases Division
HHS/ASPR/BARDA**

Dr. Donabedian focuses on the advanced development of pre-pandemic influenza vaccine capacity; next generation, broadly cross-reactive; and more effective influenza vaccines with universal vaccine potential. Most recently, he has been responsible for the advanced development of safe and effective vaccines to prevent Zika Congenital Syndrome. Dr. Donabedian is also the coordinator of various interagency initiatives to improve influenza virus vaccine production and is an active member of the Intergovernmental Select Agents and Toxins Technical Advisory Committee.

Dr. Donabedian received his PhD in Epidemiologic Science from The University of Michigan, School of Public Health under the tutelage of John Maassab, inventor of FluMist. Dr. Donabedian joined the Parke-Davis Sterile Products Division in 1989 and was responsible for the technical support of Fluogen inactivated, trivalent influenza virus vaccine and Aplisol, tuberculin skin testing reagent. Following purchase of the Sterile Products Division by King Pharmaceuticals, Dr. Donabedian served as Senior Director of Biopharmaceutical Technology and Development and as Senior Director of Pharmaceutical Technology of the Sterile Products Division. Dr. Donabedian left King Pharmaceuticals in 2006 to join HHS/ASPR/BARDA/IEDD as a K.W. Tunnell consultant in vaccine and biologics manufacturing and became a federal employee in March 2011.

Dr. Donabedian received the Secretary's Award for Distinguished Service in 2013 and 2014 for his continuing contributions to the ASPR Medical Countermeasures Team.